Online inquiry

IVTScrip™ mRNA-Anti-ERBB2, DS-8201(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6794MR)

This product GTTS-WQ6794MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets ERBB2 gene. The antibody can be applied in Breast Cancer research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001005862.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2064
UniProt ID P04626
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB2, DS-8201(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ6794MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10814MR IVTScrip™ mRNA-Anti-PD-L1&TGFBR2, M7824(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA M7824
GTTS-WQ4668MR IVTScrip™ mRNA-Anti-MSTN, BMS-986089(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BMS-986089
GTTS-WQ6882MR IVTScrip™ mRNA-Anti-CX3CL1, E-6011(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA E-6011
GTTS-WQ9648MR IVTScrip™ mRNA-Anti-CD3E&TNFRSF17, JNJ-64007957(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA JNJ-64007957
GTTS-WQ1871MR IVTScrip™ mRNA-Anti-CTLA4, AGEN1884(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA AGEN1884
GTTS-WQ6512MR IVTScrip™ mRNA-Anti-CD274, CX-072(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CX-072
GTTS-WQ9156MR IVTScrip™ mRNA-Anti-CD37, IMGN-529(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IMGN-529
GTTS-WQ10367MR IVTScrip™ mRNA-Anti-APP, LY2062430(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA LY2062430
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW